Docoh
Loading...

NYMX Nymox Pharmaceutical

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.

NYMX stock data

(
)

Calendar

11 Jun 21
2 Aug 21
31 Dec 21
Quarter (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
22 Apr 21 Robinson James George Common Stock Buy Aquire P No No 2.085 200 417 3,550,550
22 Apr 21 Robinson James George Common Stock Buy Aquire P No No 2.0882 1,100 2.3K 3,550,350
22 Apr 21 Robinson James George Common Stock Buy Aquire P No No 2.0899 2,900 6.06K 3,549,250
22 Apr 21 Robinson James George Common Stock Buy Aquire P No No 2.1 800 1.68K 3,546,350
22 Apr 21 Robinson James George Common Stock Buy Aquire P No No 2.08 51 106.08 3,545,550
22 Apr 21 Robinson James George Common Stock Buy Aquire P No No 2.0899 4,949 10.34K 3,545,499
22 Apr 21 Robinson James George Common Stock Buy Aquire P No No 2.05 5,000 10.25K 3,540,550
22 Apr 21 Robinson James George Common Stock Buy Aquire P No No 2.105 3,100 6.53K 3,535,550
22 Apr 21 Robinson James George Common Stock Buy Aquire P No No 2.1299 1,900 4.05K 3,532,450
22 Apr 21 Robinson James George Common Stock Buy Aquire P No No 2.0699 7,000 14.49K 3,530,550

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Competition
Quest DiagnosticsOrasure
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accuracy, Addressing, andthe, Augusta, besufficient, CFY, comfort, Conceptual, derecognition, disruption, downstream, draft, essential, exact, fashion, Fulfilling, fundamental, goodwill, interpretation, Inventory, investee, irrespective, mentioned, pandemic, parent, slowdown, TPS, travel, unconsolidated, understood, USD
Removed: accreted, accretion, annum, approximate, Atlanta, bid, calculation, calendar, characterized, closing, confirmed, deficient, department, estimating, implicit, lessor, lien, matured, notification, occurrence, proportion, regain, regained, subscription

Proxies

No filings

Patents

APP
Utility
Focal Treatment of Prostate Cancer
4 Feb 21
The embodiments include methods of treating prostate cancer by administering to a low grade unifocal prostate cancer tumor a composition comprising a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of a low grade unifocal prostate cancer tumor, wherein administration reduces cancer incidence, cancer grade, and cancer progression (worsening) in the entire hemi-prostate where the initial focus was located and treated.
APP
Utility
Methods of Treating Multifocal Cancer
4 Feb 21
The embodiments include methods of treating (preventing or reducing the incidence of) multifocal cancer by administering to a unifocal cancer focus a composition comprising a therapeutically effective amount of a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of the unifocal cancer tumor, wherein administration reduces multifocal cancer incidence, multifocal cancer grade, and multifocal cancer progression (worsening) in the entire organ or organism.
APP
Utility
Method of Enhancing the Therapeutic Efficacy of Fexapotide Triflutate In Treating Luts
18 Nov 20
Disclosed are methods of enhancing the therapeutic efficacy of Fexapotide Triflutate (TF) in treating LUTS, both irritative and obstructive, that include administering a composition comprising FT at least twice over a period spanning more than one year.
APP
Utility
Method of Treating Lower Urinary Tract Symptoms with Fexapotide Triflutate
18 Nov 20
Disclosed are methods of treating symptoms of Lower Urinary Tract Symptoms (LUTS), both obstructive and irritative, that include identifying patients having benign prostatic hyperplasia (BPH), and who also have LUTS, and administering a composition comprising FT to the so-identified patient.
APP
Utility
Method of Improving Lower Urinary Tract Symptoms
18 Nov 20
The embodiments include methods of improving the symptoms of mammals having LUTS, using compositions containing Fexapotide Triflutate and a pharmaceutically acceptable carrier.